1344088.1

UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF ILLINOIS

EASTERN DIVISION

CUMBERLAND PHARMACEUTICALS INC., )

)

Plaintiff, )

) C.A. No. 

v. )

)

MYLAN INSTITUTIONAL LLC, and )

MYLAN INC., )

)

Defendants. )

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiff, Cumberland Pharmaceuticals Inc. (hereinafter “Cumberland”), brings this 

Complaint for patent infringement against Mylan Institutional LLC and Mylan Inc. (hereinafter 

collectively “Mylan”). This action concerns a patent related to Cumberland’s product

Acetadote®, an intravenous formulation of N-acetylcysteine (“acetylcysteine”), widely used to 

treat suspected acetaminophen overdose to prevent or lessen hepatic injury.

Parties

l. Cumberland is a Tennessee corporation having its corporate offices and 

principal place of business at 2525 West End Ave., Suite 950, Nashville, TN 37203. 

Cumberland is engaged in the business of development, manufacture, and sale of 

pharmaceutical products.

2. On information and belief Mylan Institutional LLC is a Delaware corporation 

having its corporate offices and a place of business at 4901 Hiawatha Drive, Rockford IL

61103. On information and belief, Mylan is engaged in the development, manufacture, 

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 1 of 6 PageID #:1
2

1344088.1

marketing, and distribution of generic pharmaceutical products for sale throughout the United 

States.

3. On information and belief, Mylan Inc. is the parent company of Mylan Institutional 

LLC. Mylan Inc. is a Delaware corporation having corporate offices and a principal place of 

business at 1500 Corporate Drive, Canonsburg PA 15317. Upon information and belief 

Mylan Inc. is a large and diverse generic drug manufacturing and sales company that 

distributes and sells its products throughout the United States, including substantial sales in 

the State of Illinois. 

Jurisdiction and Venue

4. This is a complaint for patent infringement and for declaratory judgment of 

patent infringement. The jurisdiction of this Court is properly founded under 28 U.S.C. 

§§ 1331 and 1338(a) as well as 28 U.S.C. §§ 2201 and 2202.

5. Venue in this Court is proper under 28 U.S.C. §§ 1391 and 1400(b).

6. Mylan Institutional LLC resides in this district. 

7. Mylan Inc. distributes and sells its products throughout the United States, 

including substantial sales in the State of Illinois and the Northern District of Illinois. Mylan 

Inc.’s wholly owned subsidiary and agent, Mylan Institutional LLC, filed its Abbreviated New 

Drug Application (“ANDA”) for the infringing product and issued a certification under 21 

U.S.C. § 355(j)(2)(B)(ii)—the acts which give rise to the instant litigation—with knowledge 

that Cumberland would be injured by such actions in Illinois. On information and belief, 

Mylan Inc. and Mylan Institutional LLC will market and distribute the infringing product if 

approved by the FDA in this district.

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 2 of 6 PageID #:2
3

1344088.1

8. On information and belief, Mylan has maintained continuous and systematic 

contacts with Illinois and has purposefully availed itself of the privileges of doing business 

under the laws of Illinois. Thus, Mylan is subject to personal jurisdiction in this judicial 

district.

Claim for Relief

9. Cumberland is the owner of U.S. Patent No. 8,148,356 (“the ’356 patent”), 

entitled “Acetylcysteine Composition and Uses Therefor” (attached as Exhibit A), a valid 

patent, duly and legally issued on April 3, 2012.

10. A commercial embodiment encompassed by the patent-in-suit is a formulation 

of acetylcysteine currently sold by Cumberland pursuant to New Drug Application (“NDA”) 

No. 021539 under the trademark Acetadote®. Cumberland is the holder of NDA No. 021539 

for Acetadote®.

11. Acetadote® is an intravenous formulation of N-acetylcysteine. Acetadote® is 

currently used in hospital emergency departments to prevent or lessen potential liver damage 

resulting from suspected overdose of acetaminophen. Acetaminophen overdose continues to 

be the leading cause of poisonings reported by hospital emergency rooms in the United States, 

and Acetadote® has become a standard of care for treating this potentially life-threatening

condition.

12. On information and belief, Mylan filed Abbreviated New Drug Application 

(“ANDA”) No. 203624 with the United States Food and Drug Administration (“FDA”) 

seeking approval to market a generic Acetadote® formulation, which contains a certification 

under 21 U.S.C. § 355(j)(2)(B)(i) and (ii) (“Paragraph IV” Certification) that the ’356 patent is 

invalid, unenforceable, and/or not infringed.

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 3 of 6 PageID #:3
4

1344088.1

The Infringing Conduct by Defendants

Count I - Patent Infringement of the ’356 Patent

13. Cumberland realleges and incorporates by reference paragraphs 1-12.

14. By submitting its ANDA and Paragraph IV Certification under § 505(j) of the 

Federal Food, Drug, and Cosmetic Act for the purpose of obtaining approval to engage in the 

commercial manufacture, use, sale, or importation of its acetylcysteine formulation before the 

expiration of the ’356 patent, Mylan has infringed one or more claims of the ’356 patent under 

35 U.S.C. § 271(e)(2).

15. Mylan has knowledge of the ’356 patent, and Mylan’s actions constitute 

knowing and willful infringement of the valid ’356 patent.

16. As a result of Mylan’s infringement of the ’356 patent, Cumberland has 

been and will continue to be damaged unless said infringement is enjoined by this Court. 

Cumberland presently has no adequate remedy of law.

Relief Requested

Wherefore, Cumberland prays for judgment and relief including:

(A) A declaration that United States Patent No. 8,148,356 is valid and enforceable;

(B) A declaration that Mylan’s submission of ANDA No. 203624 constitutes an act 

of infringement of one or more claims of the ’356 patent under § 271(e)(2);

(C) A declaration that Mylan will infringe one or more claims of the ’356 patent by 

importing, using, offering to sell, and selling of its acetylcysteine formulation 

drug product prior to expiration of the ’356 patent;

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 4 of 6 PageID #:4
5

1344088.1

(D) A declaration that the effective date of any approval of Mylan’s acetylcysteine

formulation drug product is not to be earlier than the expiration of the ’356 

patent under 35 U.S.C. § 271(e)(4)(A);

(E) A declaration that Mylan has no legal or equitable defense to Cumberland’s 

allegations of infringement.

(F) A preliminary and permanent injunction pursuant to 35 U.S.C. § 283, enjoining 

Mylan and its officers, agents, servants, employees, privies, and others acting 

for, on behalf of, or in concert with any of them from infringing any claims of

the ’356 patent under 35 U.S.C. § 271(e)(4)(B).

(G) An accounting and award of damages incurred by Cumberland as a result of 

Mylan’s infringement if there has been commercial manufacture, use, offer to 

sell, or sale within the United States or importation into the United States under

35 U.S.C. § 271(e)(4)(C).

(H) An award declaring this case exceptional pursuant to 35 U.S.C. § 285 

and granting Cumberland its attorneys’ fees in pursuing this case and

reasonable costs and expenses incurred in this case; and

(I) Such further and other relief as this Court may deem just and proper.

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 5 of 6 PageID #:5
6

1344088.1

Dated: May 17, 2012 /s/ Lynn H. Murray

Lynn H. Murray

Claudia M. Rustad

GRIPPO & ELDEN LLC

111 South Wacker Drive

Chicago, Illinois 60606

Telephone: (312) 704-7766

Facsimile: (312) 558-1195

Laura P. Masurovsky

Mark J. Feldstein

Danielle A. Duszczyszyn

FINNEGAN, HENDERSON, FARABOW, 

GARRETT & DUNNER, LLP

901 New York Avenue, N.W.

Washington, DC 20001-4413 

Telephone (202) 408-4000

Facsimile: (202) 408-4400

ATTORNEYS FOR PLAINTIFF

CUMBERLAND PHARMACEUTICALS INC.

Case: 1:12-cv-03846 Document #: 1 Filed: 05/17/12 Page 6 of 6 PageID #:6